Hepatitis C Virus and HIV Type 1 Co-Infection

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Globally, 33 million people live with HIV; 20-30% are co-infected with Hepatitis C Virus (HCV).
• HCV is primarily blood-borne, leading to high co-infection rates (up to 90%) in intravenous drug users.
• While antiretroviral therapy (ART) improves HIV outcomes, HCV co-infection increases liver disease incidence and progression.

Purpose of the Study:

• To review current literature on HIV/HCV co-infection.
• To examine the impact of co-infection on gene expression and microRNA regulation in the human genome.
• To highlight the challenges in managing and treating co-infected individuals.

Main Methods:

• Literature review of recent studies on HIV/HCV co-infection.
• Analysis of data on disease progression and outcomes in co-infected patients.
• Exploration of molecular mechanisms, including gene expression and microRNA regulation.

Main Results:

• HIV/HCV co-infected individuals face a threefold greater risk of liver disease progression compared to HCV-monoinfected individuals.
• HCV co-infection may accelerate HIV progression to Acquired Immunodeficiency Syndrome (AIDS) and increase AIDS-related mortality.
• HCV can influence ART-induced liver toxicity, complicating HIV management.

Conclusions:

• HIV/HCV co-infection poses significant risks for accelerated liver disease and potentially faster HIV progression.
• Effective therapeutic strategies for HCV in HIV co-infected patients are lacking.
• Understanding the genomic and regulatory impact of co-infection is crucial for developing better treatments.